Kubota Vision to Present at the Ophthalmology Innovation Summit (OIS) Myopia Innovation Showcase streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Gene Therapies Market
Driven by the potential treat the root cause of diseases, the gene therapies pipeline is growing, and the market anticipated to witness substantial growth
Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.
To order this 720+ page report, which features 220+ figures and 375+ tables, please visit https://www.rootsanalysis.com/reports/view document/gene-therapies-market/268.html
Japanese Company Creates “Smart Glasses” That Can Allegedly Cure Myopia
Japan’s Kubota Pharmaceutical Holdings claims to have developed smart glasses that, if worn just an hour per day, can allegedly cure myopia.
Myopia, or nearsightedness, is a common ophthalmological condition in which you can see objects near to you clearly, but objects farther away are blurry. To compensate for this blur, you have the option of wearing eyeglasses or contact lenses, or the more invasive refractive surgery. But a Japanese company claims to have come up with a new non-invasive way of dealing with myopia – a pair of “smart glasses” that project an image from the lens of the unit onto the wearer’s retina to correct the refractive error that causes nearsightedness. Apparently, wearing the device 60 to 90 minutes a day corrects myopia.
Kubota develops myopia control spectacle prototype
Source/Disclosures Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
Kubota Vision Inc. announced it completed a myopia control wearable prototype based on Kubota Glasses technology.
Kubota stated in a press release that its research began with a tabletop optical projection device that showed axial length decreases with the use of projected myopically defocused images. Further proof-of-concept results validated the concept of wearable myopia control devices, which led to the development of the pr
Posted on 530
Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that the company achieved a milestone by completing a first spectacle-style wearable prototype based on Kubota Glasses technology.
(1) Kubota Vision conducted a clinical study in early 2020 with an electronic tabletop optical projection device that embodied Kubota Glasses technology; (2) The company also completed a successful proof-of-concept (POC) clinical study to validate the concept of a wearable myopia-control device based on Kubota Glasses technology in August 2020; (3) Based on these results, the company has completed the first spectacle-style wearable prototype based on Kubota Glasses technology. (Photo: Business Wire)